Table 2 Patient and tumor characteristics
| ITT N = 55 | ITT2 N = 35 | ||
|---|---|---|---|
| n % | n % | ||
| Gender | Male | 30 (55) | 22 (63) |
| Female | 25 (45) | 13 (37) | |
| Age | Mean | 61 | 61 |
| SD | 10.5 | 9.4 | |
| Range | 53–69 | 51–69 | |
| Primary tumor present at baseline | 16 (29) | 12 (34) | |
| ECOG PS | 0 vs 1 | 55 (100) | 35 (100) |
| Stage at initial diagnosis | I | 1 (2) | 1 (3) |
| II | 2 (4) | 0 | |
| III | 12 (22) | 8 (23) | |
| IV | 40 (73) | 26 (74) | |
| Number of site (s) involved | 1 | 12 (22) | 8 (23) |
| 2 | 20 (36) | 15 (43) | |
| >2 | 23 (42) | 12 (34) | |
| Prior therapies received | |||
| Fluoropyrimidines | 55 (100) | 35 (100) | |
| Oxaliplatin | 53 (96) | 35 (100) | |
| Irinotecan | 55 (100) | 35 (100) | |
| VEGF inhibitorsa | 53 (96) | 34 (97) | |
| EGFR inhibitorsb | 27 (49) | 20 (57) | |